Evan Seigerman
Stock Analyst at BMO Capital
(4.05)
# 545
Out of 5,127 analysts
152
Total ratings
54.9%
Success rate
11.18%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Outperform | $35 → $54 | $38.08 | +41.81% | 3 | Dec 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,100 → $1,200 | $1,088.06 | +10.29% | 10 | Dec 4, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $120 → $130 | $120.79 | +7.62% | 18 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $473.05 | +12.04% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $106.27 | -43.54% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $79.10 | +51.71% | 6 | May 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $136.72 | -15.89% | 15 | May 6, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $184.33 | -24.59% | 27 | Feb 13, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $56.41 | +8.14% | 11 | Nov 12, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $67.21 | -40.48% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $40 | $8.42 | +375.06% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $811.60 | -2.91% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $8.73 | -71.36% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $330.98 | -26.58% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $5.62 | +113.52% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $25.24 | +137.72% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.76 | +1,604.55% | 3 | May 12, 2020 |
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $35 → $54
Current: $38.08
Upside: +41.81%
Eli Lilly and Company
Dec 4, 2025
Maintains: Outperform
Price Target: $1,100 → $1,200
Current: $1,088.06
Upside: +10.29%
Gilead Sciences
Aug 8, 2025
Maintains: Outperform
Price Target: $120 → $130
Current: $120.79
Upside: +7.62%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $473.05
Upside: +12.04%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $106.27
Upside: -43.54%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $79.10
Upside: +51.71%
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $136.72
Upside: -15.89%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $184.33
Upside: -24.59%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $56.41
Upside: +8.14%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $67.21
Upside: -40.48%
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $8.42
Upside: +375.06%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $811.60
Upside: -2.91%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $8.73
Upside: -71.36%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $330.98
Upside: -26.58%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $5.62
Upside: +113.52%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $25.24
Upside: +137.72%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.76
Upside: +1,604.55%